## LVS: Las Vegas Sands Corp. - XLY: Consumer Cyclical

### Executive Summary

VALUE thesis: PEG 0.86 indicates fundamental undervaluation. Quality metrics strong (ROE 66%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($62.94)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Lido Advisors LLC Lowers Position in Las Vegas Sands Corp. $LVS**
- Source: MarketBeat | 20251210T105805 | Neutral | Relevance: 99%
-  Lido Advisors LLC has significantly reduced its stake in Las Vegas Sands Corp. (NYSE:LVS) by 83.2% in the second quarter, holding 5,194 shares valued at $226,000. Despite this, other institutional investors like Norges Bank and Schroder Investment Management Group have either opened new positions or increased their holdings. Analysts maintain a "Moderate Buy" rating for LVS after various price target adjustments, while heavy insider selling by the CFO and COO has also been reported.

**2. Zacks Industry Outlook Highlights Las Vegas Sands, Rush Street Interactive and Brightstar Lottery**
- Source: TradingView | 20251211T100907 | Bullish | Relevance: 98%
-  The Zacks Gaming industry faces challenges from strained consumer spending and regulatory complexity but benefits from rising Macau gaming revenues and strong sports betting demand. Despite a "Dull Prospects" ranking, companies like Las Vegas Sands, Rush Street Interactive, and Brightstar Lottery show strong fundamentals and are recommended for investment. The industry has underperformed the S&P 500 but outperformed the broader Consumer Discretionary sector in the past year.

**3. The Manufacturers Life Insurance Company Sells 276,521 Shares of Las Vegas Sands Corp. $LVS**
- Source: MarketBeat | 20251211T141842 | Neutral | Relevance: 98%
-  The Manufacturers Life Insurance Company reduced its stake in Las Vegas Sands Corp. (NYSE:LVS) by 5.2%, selling 276,521 shares and now owning 0.74% of the company worth $220.14 million. This reduction follows significant insider selling by the CFO and COO, who together sold over 190,000 shares recently. Despite insider selling, analysts maintain a "Moderate Buy" rating for LVS with an average target price of $65.80, and the company recently beat earnings estimates and announced a quarterly dividend.

**4. The Bull Case For Las Vegas Sands (LVS) Could Change Following Executive Share Sales And Rising Short Interest - Learn Why**
- Source: Simply Wall Street | 20251209T162121 | Neutral | Relevance: 98%
-  Recent executive share sales and increased short interest in Las Vegas Sands (LVS) are raising investor concerns, despite the company's refocused strategy on Asian integrated resorts and positive Macau casino revenue data. These bearish signals are prompting a reevaluation of the investment narrative, even as the company projects significant revenue and earnings growth by 2028 based on its Asian market focus. The mixed signals highlight a tension between insider actions and fundamental drivers in the investment landscape.

**5. Sands China (NYSE: LVS) marks 12th year, builds 30,000 hygiene kits for families**
- Source: Stock Titan | 20251211T143042 | Bullish | Relevance: 98%
- Sands China, a subsidiary of Las Vegas Sands Corp. (NYSE: LVS), mobilized 330 staff and volunteers to assemble 30,000 hygiene kits for the "Clean the World" initiative, marking its 12th year of participation. Of these kits, 26,000 will go to the Philippines, and 4,000 will be distributed among NGOs in Macao and Hong Kong. This effort is part of Sands China's broader Sands Cares and ECO360 sustainability programs, which have recycled 345 tons of hotel amenities and produced over 415,000 kits since 2014.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | UBS | $68 | $67 | +1% |
| 2025-12-01 | Argus Research | $80 | $65 | +23% |
| 2025-11-18 | Wells Fargo | $66 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | UBS | main | Neutral |
| 2025-12-01 | Argus Research | main | Buy |
| 2025-11-18 | Wells Fargo | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($13.25M) |
| Sells | 12 ($64.93M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 24.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 6.2% (-2.0%)
- Capital Research Glo: 5.0% (-30.9%)
- Blackrock Inc.: 4.0% (-0.1%)
- Price (T.Rowe) Assoc: 2.2% (-7.8%)
- State Street Corpora: 2.1% (-7.2%)

### Key Risks

1. Heavy insider selling: $65M sold (12 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Forward P/E 20.8x stretched relative to 10% growth. Quality metrics strong (ROE 66%). Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($64.9M in 90 days), potential headwind. Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $45.4B |
| Beta | 0.97 |
| 52W Range | $30.18 - $70.45 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 20.8 |
| Current P/E | 22.8 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at -2.3% (minimal 5-day change). Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.35x) but short-term weakness (below SMA20). MACD histogram bearish (-0.52), momentum weakening. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.26% (CS: 28) | Weak |
| RSI_14 | 56.9 | Neutral |
| MACD Histogram | -0.52 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.101x | Above |
| vs SMA200 | 1.347x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $66.20
- **Stop Loss:** $62.94 (4.9% risk)
- **Target:** $72.72 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 423
- **Position Value:** $28,002.60
- **Portfolio %:** 28.00%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-28 (Est: $0.75)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.78 | +25.4% |
| 2025Q2 | $0.53 | $0.79 | +48.9% |
| 2025Q1 | $0.57 | $0.59 | +3.8% |
| 2024Q4 | $0.58 | $0.54 | -6.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*